1124 related articles for article (PubMed ID: 23562920)
1. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
3. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
[TBL] [Abstract][Full Text] [Related]
6. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; Yen KC; See LC; Chang SH; Wu LS; Lee HF; Tu HT; Yeh YH; Kuo CT
Stroke; 2016 Feb; 47(2):441-9. PubMed ID: 26732563
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
[TBL] [Abstract][Full Text] [Related]
10. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
[TBL] [Abstract][Full Text] [Related]
12. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Rosenzweig M; Lane DA; Lip GY
Am J Med; 2014 Apr; 127(4):329-336.e4. PubMed ID: 24361757
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
14. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
[TBL] [Abstract][Full Text] [Related]
19. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
